Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / COMMON-STOCK
-
Shares outstanding
-
72.2M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
44.3M
-
Shares change
-
+1.4M
-
Total reported value, excl. options
-
$2.04B
-
Value change
-
+$46.9M
-
Put/Call ratio
-
0.28
-
Number of buys
-
57
-
Number of sells
-
-68
-
Price
-
$46.14
Significant Holders of Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) as of Q1 2022
154 filings reported holding ZNTL - Zentalis Pharmaceuticals, Inc. - COMMON-STOCK as of Q1 2022.
Zentalis Pharmaceuticals, Inc. - COMMON-STOCK (ZNTL) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.3M shares
of 72.2M outstanding shares and own 61.34% of the company stock.
Largest 10 shareholders include FMR LLC (6.74M shares), Matrix Capital Management Company, LP (4.35M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.2M shares), VANGUARD GROUP INC (3.24M shares), Avidity Partners Management LP (3.18M shares), BlackRock Inc. (2.84M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.43M shares), STATE STREET CORP (2.08M shares), VIKING GLOBAL INVESTORS LP (2.03M shares), and PRIMECAP MANAGEMENT CO/CA/ (1.21M shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.